Skip to content
DataLookout
Menu

NCT06772415

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors

StatusTerminated
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: The sponsor adjusted its research and development strategy Show 4 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Primary completion date changed from estimate of Dec 2028 to Oct 22, 2026
    • Start date: Jan 8, 2025 to Jan 2, 2025
    • Study sites revised (9)
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 3 to 9
    • Start date changed from estimate of Jan 2025 to Jan 8, 2025
    v2
  3. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

Dose escalation: Incidence of dose-limiting toxicities (DLTs).
Timeframe: 2 years
Dose expansion: Objective response rate (ORR) evaluated by investigator based on response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
Timeframe: 3 Years

Secondary (7)

Incidence and severity of TEAEs.
Maximum Plasma Concentration (Cmax) of Gensci122
Time to Maximum Plasma Concentration (Tmax) of Gensci122
Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval for Gensci122
Duration of Response (DOR)
Show 2 moreShow less
Progression-free Survival (PFS)
Overall Survival (OS)

Arms and interventions

Single armExperimental

Drugs: GenSci122 tablet 50mg, GenSci122 tablet 250mg

Sites

9 sites in 1 country